49619-59-2

Basic information

• Product Name: 5-Methoxy-4-oxo-4H-chroMene-3-carbaldehyde
• Synonyms: 5-Methoxy-4-oxo-4H-chroMene-3-carbaldehyde
• CAS NO: 49619-59-2
• Molecular Formula: C₁₁H₈O₄
• Molecular Weight: 204.17882
• Mol File: 49619-59-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 366.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.401±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 5-Methoxy-4-oxo-4H-chroMene-3-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxy-4-oxo-4H-chroMene-3-carbaldehyde(49619-59-2)
• EPA Substance Registry System: 5-Methoxy-4-oxo-4H-chroMene-3-carbaldehyde(49619-59-2)

Safety Data

• Hazardous Substances Data: 49619-59-2(Hazardous Substances Data)

Upstream product

• 699-83-2 2,6-dihydroxylacetophenone 
• 79-37-8 oxalyl dichloride 
• 703-23-1 2'-hydroxy-6'-methoxyacetophenone 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1160309-63-6 (E)-5-methoxy-3'-nitro-3-styrylchromone 
• 1307915-51-0 9-methoxy-10-oxo-3-phenyl-4a,10-dihydropyrano[4,3-b]chromene-4-carbaldehyde 
• 1448991-92-1 dimethyl 3-(2-hydroxy-6-methoxybenzoyl)-6,7,12,12b-tetrahydroindolo[2,3-a]quinolizine-1,12b-dicarboxylate 
• 1422452-73-0 (E)-5-methoxy-3-(3-(4-(4-methoxybenzyloxy)phenyl)-3-oxoprop-1-enyl)-4H-chromen-4-one 
• 1422452-59-2 (E)-3-(3-hydroxy-3-(4-hydroxyphenyl)prop-1-enyl)-5-methoxy-4H-chromen-4-one 
• 1422452-47-8 (E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-enyl)-5-methoxy-4H-chromen-4-one 
• 652968-78-0 (Z)-5-methoxy-4'-nitro-3-styrylchromone 

Relevant articles and documents

Synthesis of Chromeno[2,3-d]pyrimidin-5-one Derivatives from 1,3,5-Triazinanes via Two Different Reaction Pathways

1,3,5-Triazinanes, as a kind of versatile building block, are applied in the synthesis of chromeno[2,3-d]pyrimidin-5-one derivatives via two different reaction modes, which perfectly exhibits the powerful function of 1,3,5-triazinane as a three-atom synth

Synthesis and biological evaluation of N-Aryl-N′-(5-(2-hydroxybenzoyl) pyrimidin-2-yl)guanidines as toll-like receptor 4 antagonists

Background: Toll-like receptor 4 (TLR4) has been associated with several inflammatory diseases, such as sepsis, atherosclerosis and chronic pain. Objective: The aim of the present study was to develop an efficient and straightforward synthetic approach for the preparation of small-molecule antagonists Naryl-N′-(5-(2-hydroxybenzoyl)pyrimidin-2-yl)guanidines in order to evaluate these for TLR4 antagonist activity and to obtain useful information about their structure-activity relationships. Methods: The present work have designed and optimized a three-step synthetic route for derivatives of a previously demonstrated antagonist of TLR4: 1-(4-fluorophenyl)-2-(5-(2-hydroxy-5-methoxybenzoyl)pyrimidin-2-yl)guanidine. The antagonist activities of eight novel synthesized compounds were evaluated on cells which selectively express TLR4. Results: Three guanidine derivatives showed promising antagonist activities, with IC50 values in the low micromolar range. Conclusion: Our findings represent an important starting point for further studies of small-molecule agents targeting Toll-like receptors.

Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: Synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression

A library of conjugates of chromones and 2,4-thiazolidinedione has been synthesized by Knoevenagel condensation followed by reduction using hydrogen gas and Pd/C as a catalyst. Compounds 5c and 5e were most effective in lowering the blood glucose level comparable to standard drug pioglitazone. Compound 5e exhibited potent PPAR-γ transactivation of 48.72% in comparison to pioglitazone (62.48%). All the molecules showed good glide score against the PPAR-γ target in molecular docking study. PPAR-γ gene expression was significantly increased by compound 5e (2.56-fold) in comparison to standard drug pioglitazone. Compounds 5e and 5c did not cause any damage to the liver and may be considered as promising candidates for the development of new antidiabetic agents.